關於我們

我們的專業

合度生技的使命，即是希望可以透過全球負擔得起的非侵入性早期癌症檢測和管理，達到早期發現癌症和進行管理，我們建立了一個涵蓋多項專業的專家團隊，包括循環腫瘤細胞、影像處理、次世代定序、精準醫學、和癌症診斷商品。

合度生技的CMxTM平台為中央研究院技轉出來的專利技術，能夠偵測微乎其微的循環腫瘤細胞(CTC)，希望達到早期偵測、早期治療的理念與想法！除了循環腫瘤細胞技術(CTC)，我們也運用次世代定序(NGS)來分析循環腫瘤DNA，期許能夠實現我們改變癌症檢測和管理的目標。

Atul Sharan

Chief Executive Officer
執行長

Rui Mei, PhD

Chief Scientific Officer
首席科學官

Drew Watson, PhD

Sr. VP of Clinical Studies & Biostatistics
生物統計及臨床研究資深副總

Jen-Chia Wu, PhD

CTC Capture Technology
CTC抓取技術

Ben Hsieh, PhD

CTC Image Analysis
CTC影像分析

Hung-Jen Shao, PhD

CTC Instrumentation
CTC自動化儀器開發

Anthony Lin, PhD

CTC RNA Analysis
CTC RNA分析

Stephen Su, PhD

Product
產品開發與定位

Si-Hong Lu, PhD

CTC DNA Analysis
CTC DNA分析

Zulfiqar Gulzar, PhD

NGS Assay Development
NGS檢測開發

Pratyush Gupta, PhD

ctDNA Assay Development
ctDNA檢測開發

Jr-Ming Lai, PhD

Data Analysis
ctDNA檢測開發

Alex Atkins, M.S.

Bioinformatics
生物資訊

Julian Lucas

Bioinformatics
生物資訊

Atul Sharan

Chief Executive Officer
執行長

Akhil Saklecha

MD Board Member
董事會會員

Amit Shah

Board Member
董事會會員

Stan Shih (施振榮)

Board Observer
董事會觀察員

Yuchiro Morimoto

CEO, Silicon Valley Venture Fund, Board Member
執行長；矽谷創投；董事會會員

Ying-Chih Chang, Ph.D.
張瑛芝教授

CoFounder and Research Fellow Academia Sinica; Consulting Professor, Stanford University
共同創立者與中研院技術研究員
史丹福大學顧問教授

Ashish Nimgaonkar, MD

Assistant Professor of Medicine Johns Hopkins; Associate Medical Director
CBID
約翰霍普金斯醫學院助理教授
CBID副醫學主任

David R. Gandara, MD

Professor of Medicine at the University of California at Davis School of Medicine
加州大學戴維斯分校 醫學院教授

Mark Pegram, MD

Professor Stanford University; Director, Breast Cancer Oncology Program, Women’s Cancer Center
史丹福大學教授； 婦女乳癌中心研究主任

Mahul Amin, MD

Chair, Dept. of Pathology, College of Medicine Univ. of Tennessee Health Science Center;
田納西健康科學中心大學醫學院 病理醫學系主任

UTHSC Gerwin Chair for Cancer Research

Dave Lawrence, MD

Advisor, Artiman Ventures; Former CEO & Chairman, Kaiser Foundation Health Plan and Hospitals
Artiman Ventures 顧問
Kaiser Foundation 健康計畫與醫院的前任執行長與主席

Shai Friedland, MD

Chief of Gastroenterology & Hepatology, VA Palo Alto Health Care System, Stanford University
肝膽腸胃科主任 VA Palo Alto 健康照護中心
史丹佛大學

Atul Sharan

Chief Executive Officer

In 2012, as an Entrepreneur in Residence at a leading Silicon Valley Venture Firm, Artiman Ventures, Atul Sharan co-founded CellMax Life, applying semiconductor industry principles to a proprietary Circulating Tumor Cell (CTC) bio-mimetic CMx platform to develop affordable, clinically proven blood-tests for Early Cancer Detection and Treatment. He was motivated to start CellMax as two members of his family have been diagnosed with cancer – one of them was diagnosed with breast cancer within two weeks of receiving a conclusively negative mammogram. Atul is a veteran of the high-tech industry with experience as an engineer, serial entrepreneur, CEO and angel investor. He specializes in identifying unmet market needs and matching them with early-stage technologies to achieve dramatically better results than prevailing standards. He has done that successfully multiple times: AutoESL (acquired by Xilinx); ClearShape Technologies (acquired by Cadence), Numerical Technologies (Nasdaq IPO; acquired by Synopsys); Ambit Design (acquired by Cadence). Atul holds a BS in Engineering from IIT-India; MS in Engineering from UH, Texas and an MBA from UC-Berkeley.

Dr Rui Mei

Chief Scientific Officer & VP of R&D

As Chief Scientific Officer at CellMax Life, Dr Mei leads a global team of R&D scientists, CLIA and CAP laboratory professionals, bioinformaticians and software engineers. She is responsible for the development of CellMax Life’s multi-biomarker platforms, including the circulating tumor cell (CTC) CMxTM, Next Generation Sequencing “SMSEQ, Methylation and Protein expression platforms. Prior to joining CellMax Life, Dr Mei was Vice President of R&D and Genomic Service Operations, and part of the founding team at Centrillion Biosciences where she established their next-generation sequencing for services to pharmaceutical companies, researchers and physicians. At Affymetrix, a pioneer in multi-biomarker analysis tools, Dr Mei led the development of multiple products for genotyping, re-sequencing, and gene expression analysis. She received her PhD in Biochemistry from the University of Michigan, Ann Arbor, and post-doctoral training in Nucleic Acid Enzymology at Stanford University. Dr Mei has published over 40 articles in peer-reviewed scientific journals and holds 20 patents.

Mana Javey, MD, PhD

Medical Director

Dr Javey is responsible for the regulatory approvals and accreditation of CellMax Life’s laboratories and is also responsible for Medical and Scientific Affairs. She is an authority on laboratory accreditation requirements for Circulating Tumor Cell technology. She led regulatory filings with the CMS (Centers for Medicare Services) and the College of America Pathologists which resulted in successful CLIA accreditation of the CellMax Life laboratory in Sunnyvale, California, and CAP accreditation of the company’s labs in both Taipei, Taiwan and Sunnyvale, California. Dr Javey holds MD, and PhD in immunology and biochemistry. She did her pathology residency training at University of California, San Francisco, and a postdoctoral fellowship at Stanford University, School of Medicine. She has won numerous institutional and national awards including the Dean’s Fellowship at Stanford and co-authored several peer-reviewed publications.

Padma Sundar

VP of Marketing and Business Development

At CellMax Life, Padma is responsible for worldwide marketing and business development. Padma has over 20 years of global life sciences strategy, marketing and product commercialization experience. Prior to CellMax, Padma led marketing for Guardant Health, including physician and patient education, and establishing product requirements for the company’s LDT and IVD tests, leading to a 100% increase in test volume and adoption by 60% of US medical oncologists. Prior to that, Padma led oncology product marketing at Ariosa (Roche Sequencing) where she defined product requirements, branding and launch plan for the “Avenio” liquid biopsy kits now successfully commercialized worldwide. Padma was head of oncology product marketing and business development for Affymetrix’s cancer portfolio including DNA, RNA and Protein expression products, including the “OncoScan” whole genome cancer profiling assay, which is available in 50 leading clinical laboratories and CROs worldwide. Padma began her career at McKinsey & Company as a consultant in the biopharmaceutical practice. She has an MBA-MPH from UC Berkeley and a Bachelors in Chemistry.

Bio Information In Progress

Please check back soon.

合度精密生物科技有限公司

合度精密生物科技有限公司是一家領先的癌症檢測公司，其使命是透過全球皆負擔得起的非侵入性檢測來早期發現和管理癌症。合度生技專利的循環腫瘤細胞技術(CTC)以及運用次世代定序(NGS)來分析循環腫瘤DNA的技術，已經能夠提供健康人與癌症病患更精準的醫療解決方案。

美國總部

1271 Oakmead Parkway Sunnyvale, CA 94085 Phone: +1 650-564-3905

台灣辦公室

18F-1 Park Street Nangkang, Taipei City (+886) 0800-555-885 (Taiwan)

© 2018 CellMax Life | All Rights Reserved | Terms and Conditions | Privacy Policy

TOP